N-Acetylcysteine in Neurological Disorders: A Systematic Review of Clinical and Translational Evidence Across Seven Disorders
International Journal of Molecular Sciences · 27.03.2026 · 27 (7) · 3076
DOI: 10.3390/ijms27073076 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 27.03.2026. Verfasst von Robert Mîndreanu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology, Iuliu Hațieganu University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania. Hauptthemen laut MEDLINE: Acetylcysteine, Nervous System Diseases, Neuroprotective Agents. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
N-acetylcysteine (NAC) is a glutathione precursor with established antioxidant and anti-inflammatory properties that has been investigated as a neuroprotective agent across multiple neurological conditions. This systematic review systematically mapped the clinical evidence for NAC across seven neurological disorders. PubMed and Cochrane Library were searched for studies published between 1 January 1995 and 31 December 2025. Twenty-three studies were included: traumatic brain injury (TBI, n = 6), Alzheimer’s disease (AD, n = 5), Parkinson’s disease (PD, n = 5), multiple sclerosis (n = 4), amyotrophic lateral sclerosis (n = 2), and migraine (n = 1); no eligible epilepsy studies were identified. The strongest evidence emerged for acute mild TBI, where early NAC administration significantly improved symptom resolution, and for PD, where combined intravenous/oral NAC improved dopamine transporter binding. In AD, nutraceutical formulations including NAC and other active compounds showed trends toward cognitive stabilization. Most included studies had a high or serious risk of bias, and only eight of 23 assessed oxidative stress biomarkers. NAC demonstrated a favorable safety profile across all conditions. Despite fragmented and heterogeneous evidence, the encouraging signals identified warrant large-scale randomized controlled trials with a standardized biomarker assessment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Physiology, Iuliu Hațieganu University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania.
- Department of Neuroscience, Iuliu Hațieganu University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania.
ORCID-Profile: Robert Mîndreanu, Irina Camelia Chiș, Simona Clichici, Șoimița Suciu
Zitieren
APA
Mîndreanu, R., Chiș, I. C., Sevastre-Berghian, A., Login, C., Stan, A., Stan, T., Clichici, S., & Suciu, Ș. (2026). N-Acetylcysteine in Neurological Disorders: A Systematic Review of Clinical and Translational Evidence Across Seven Disorders. International Journal of Molecular Sciences, 27(7), 3076. https://doi.org/10.3390/ijms27073076
Vancouver
Mîndreanu R, Chiș IC, Sevastre-Berghian A, Login C, Stan A, Stan T, et al. N-Acetylcysteine in Neurological Disorders: A Systematic Review of Clinical and Translational Evidence Across Seven Disorders. International Journal of Molecular Sciences. 2026;27(7):3076. doi:10.3390/ijms27073076
BibTeX
@article{Mndreanu2026,
author = {Mîndreanu, Robert and Chiș, Irina Camelia and Sevastre-Berghian, Alexandra and Login, Cezar and Stan, Adina and Stan, Teodora and Clichici, Simona and Suciu, Șoimița},
title = {N-Acetylcysteine in Neurological Disorders: A Systematic Review of Clinical and Translational Evidence Across Seven Disorders},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {7},
pages = {3076},
doi = {10.3390/ijms27073076}
}
EUVIMED